Plain-English translation of NCT07067749 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new, faster way to diagnose muscle-invasive bladder cancer using an advanced MRI scan. Instead of the standard approach that requires multiple procedures, doctors will use MRI imaging to confirm the cancer has invaded the muscle layer, which may allow patients to skip an additional procedure and move directly to definitive treatment.
Current diagnosis of aggressive bladder cancer involves multiple time-consuming steps that can delay treatment. This trial exists to see if the new MRI-based approach can reduce delays and get patients to their final cancer treatment sooner, which could improve their long-term outcomes.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will have a bladder examination and biopsy (standard care). Then, depending on which group you're assigned to, you'll either receive an advanced MRI scan (new approach) or proceed with a standard surgical procedure for staging (usual care). Blood samples will be collected at planned timepoints to measure cancer markers. Your doctors will track how quickly you move through the diagnostic process to definitive treatment.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
Italy